HLA-A and acute myeloid leukemia: For example, the NPM1mut epitope described above (74) is only presented by the ~15% of AML patients with NPM1mut (30–35%) and HLA-A*02:01 (~50% in the U.S.A.)and this represents one of the most broadly applicable recurrent neoantigens in hematologic malignancies.